Oral semaglutide studies demonstrated similar weight loss patterns when taken at equivalent therapeutic doses, though the higher pill strength needed to achieve bioavailability sometimes caused more gastrointestinal side effects in early treatment weeks
Fat-binding capacity Fat-binding capacity (FBC) was determined according to the method described by zdemir [40]
Dementia risk is complex, and GLP-1 therapy has risks, contraindications, and monitoring needs
The bioavailability factor Not all GHK-CU reaches target tissues equally
However, no major safety concerns have arisen to date, although definitive conclusions for pancreatic cancer, thyroid cancer and DRP complications cannot be drawn at this point
Many reproductive health providers recommend switching to a LARC when starting GLP-1 therapy if pregnancy prevention is critical